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Elderly patients are vulnerable to the adverse neurological effects of antipsychotics, particularly
Parkinsonian symptoms and tardive dyskinesia. This vulnerability in the elderly becomes complex and
unpredictable when aripiprazole is prescribed to replace other second-generation or ﬁrst-generation
antipsychotics. This report describes a 69-year-old female schizophrenic patient, who received aripi-
prazole after using a few antipsychotics, including the ﬁrst- and second-generation ones. The tardive
dyskinesia developed 6 weeks after switching to aripiprazole but subsided 4 weeks later when stopping
the concurrent amantadine and decreasing the dosage of trihexyphenidyl. However, Parkinsonian
symptoms developed insidiously thereafter, which remitted after the dosage of trihexyphenidyl was
increased again. The possible mechanisms of the alternated adverse neurological events after a switch to
aripiprazole in the chronic elderly psychosis are discussed.
Copyright  2012, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
The number of elderly psychiatric patients treated with
a second-generation antipsychotic has increased signiﬁcantly in
recent years. Aripiprazole, a second-generation antipsychotic, is
a partial agonist on the dopamine type-2 (D2) and serotonin type-1
(5-HT1A) receptors as well as a full antagonist on the serotonin
type-2 (5-HT2A) receptor1,2. At the therapeutic dosage of 10e30 mg/
day, aripiprazole is generally well tolerated, and the manufacturer
lists an overall incidence of extrapyramidal syndrome of 6% with
aripiprazole3. However, elderly patients are vulnerable to adverse
neurological effects of antipsychotics, particularly Parkinsonian
symptoms and tardive dyskinesia (TD). This vulnerability becomes
complex and unpredictable when aripiprazole is used in place of
other second- or ﬁrst-generation antipsychotics1,3e5. Reports of
adverse neurological effects induced by aripiprazole and their
clinical courses have increased our understanding of the mecha-
nisms underlying those adverse events and how to optimize the
therapeutic switch from other antipsychotics to aripiprazole1,3e5.ment of Psychiatry, Mackay
Chu-Wei, Tam-Shui, Taipei
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who developed 4-week temporary TD at 6 weeks after the switch to
aripiprazole. The TD disappeared after stopping concurrent aman-
tadine use and decrement of trihexyphenidyl; however, insidious
Parkinsonian symptoms developed thereafter. The possible mecha-
nisms of the alternated adverse neurological events after a switch to
aripiprazole in chronic elderly psychosis are discussed.
2. Case report
Mrs. A, aged 69, was diagnosed with a schizophrenic disorder
roughly 30 years ago. No substance, such as amphetamines, or
alcohol use disorder was noted. The patient presented to the
psychiatric outpatient clinic at a general hospital after experiencing
bucco-lingual-masticatory movement for 2 weeks. Aripiprazole
was used for 2 months concurrent with amantadine and trihex-
yphenidyl. Treatment with aripiprazole was continued because of
its efﬁcacy for psychotic symptoms, but amantadine and trihex-
yphenidyl treatment was stopped under the impression of TD.
Within 2 weeks, the patient’s TD subsided, but Parkinsonism-like
symptoms developed gradually during the following 2 weeks.
Fortunately, overall involuntary movements remitted in the
following year after increasing the trihexyphenidyl dosage to
10 mg/day.
The patient’s long-term psychiatric treatment history was
reviewed. This patient began attending our psychiatric clinic 9cy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
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syndrome, bradykinesia and rigidity, secondary to the use of ﬂu-
pentixol at 3 mg/day. No apparent positive symptoms, like auditory
hallucinations or delusion, existed under ﬂupentixol treatment. The
patient denied any family history of major neurological disorders or
involuntary movement. The adverse neurological effect of
Parkinsonism-like syndrome was very distressing with obvious
social functioning impairment. The patient was therefore
prescribed amantadine at 200 mg/day, and the trihexyphenidyl
dosagewas increased from 4 to 10 mg/day.With thesemedications,
the patient lived a reasonable life with mild but persistent
Parkinsonian-like symptoms until 3 years ago, when further
dyskinetic movements of her lower lip and oral area developed. The
antipsychotic was then switched to risperidone at 3 mg/day brieﬂy,
and then changed to amisulpride at 400 mg/day due to intolera-
bility. To further decrease the Parkinsonism-like syndrome and
peri-oral dyskinesia, amantadine at 200 mg and trihexyphenidyl at
10 mg/day were maintained, and the amisulpride dosage was
reduced to 200 mg/day about 1 year ago. Both adverse neurological
symptoms subsided gradually. At that time, the Abnormal Invol-
untary Movement Scale (AIMS)6 was used to measure her motor
dysfunction and the score was 2. However, her psychotic symp-
toms, such as auditory hallucinations, irritability, and delusion of
persecution, relapsed. Therefore, amisulpride was switched to ari-
piprazole at 10 mg/day, and the same trihexyphenidyl and aman-
tadine dosages were maintained. Her psychotic symptoms
improved gradually over 1 month. However, involuntary bucco-
lingual-masticatory movements developed 2 months later with
an AIMS score of 12 and a global severity of 3. Dyskinesia features
were grimacing; tongue protruding, squirming, and twisting; lip
smacking; blowing of cheeks; chewing; puckering and pursing of
lips; and rapid eye blinking. Dyskinetic movements persisted
during alert hours and severely affected normal eating and
drinking. No abnormal movement of her trunk, hips, extremities,
and ﬁngers was noted. A brain computed tomography scan and
laboratory test results were normal. No dementia features were
found. Under the impression of TD, amantadine was discontinued
and trihexyphenidyl was tapered off to 4 mg/day. Dramatically,
bucco-lingual-masticatory movements disappeared in 2 weeks.
However, a Parkinsonism-like syndrome developed gradually 2
weeks later with noticeable rigidity, bilateral pill-rolling tremors,
bradykinesia, stooped posturing, limb shaking, coarse tremors,
saliva discharge, a mask-like face, and difﬁculty in walking. The
patient’s AIMS score was 6 with a global severity of 1. The trihex-
yphenidyl dosage was therefore increased to 10 mg/day, and
remission of this neurological event was achieved in 2e3 weeks.
The patient showed no TD or Parkinsonism-like syndrome in the
following year.
3. Discussion
Elderly patients are vulnerable to adverse neurological events,
such as Parkinsonian symptoms and TD, when using various anti-
psychotics. The latent period from initiating an antipsychotic to the
development of Parkinsonian symptoms is typically shorter than
that to TD. Some possible factors likely explain why TD occurred in
advance of Parkinsonian symptoms in this elderly patient after
switching to aripiprazole. First, a dopamine partial agonist such as
aripiprazole takes time to stabilize dopaminergic transduction
under an unstable brain microenvironment. The dopaminergic
actions of aripiprazole (e.g., agonist, partial agonist, or antagonist)
depend on the precise cellular milieu. In this patient, long-term use
of various ﬁrst- and second-generation antipsychotics may have
altered dopaminergic functioning as a ﬂuctuating status; thus, pre-
dicting the response in a given tissue is difﬁcult, particularly underpathological conditions7,8. Second, extrapyramidal symptoms may
develop at the too high dopaminergic tone (e.g., chorea) or too low
condition (e.g., Pakinsonism), which is also affected by acetylcholine
functioning. A partial dopamine agonist has less activity than natural
dopamine and needs reduced acetylcholine function to maintain
a balance between these two neurotransmitters and thereby
prevent involuntary movement. The dopaminergic tone (associated
with amantadine) and anticholinergic tone (associated with tri-
hexyphenidyl) in the nigrostriatal dopamine system modify the
functional manifestation of aripiprazole and promote D2 receptor
activation, explaining the emergence of TD in this patient, as indi-
cated in previous reports1,3,5,9. Third, a decreased brain neuron
reserve makes elderly people sensitive to the adverse neurological
effect of a dopamine partial agonist10. Finally, themotor abnormality
inherent in this schizophrenic patientmay increase TD vulnerability.
Moreover, aripiprazole is a 5-HT2A receptor antagonist that increases
dopamine release5, which may contribute to the appearance of TD
under dopamine receptor supersensitivity.
The widely accepted mechanism of antipsychotic-induced TD is
correlated with prolonged blockade of postsynaptic dopamine
receptors and its aftermath of dopaminergic upregulation at the
nigrostriatal pathway2,8,11. When aripiprazole functioned like
a dopamine full agonist on the supersensitive dopaminergic
receptors and resulting in the development of TD, concurrent usage
of amantadine9 (further increasing dopaminergic functioning) and
trihexyphenidyl (affecting the balance between dopamine and
acetylcholine) may exacerbate this adverse event. However, dopa-
minergic supersensitivity decreased gradually under the contin-
uous use of aripiprazole. Amantadine was discontinued and the
trihexyphenidyl dosage was tapered off soon after TD developed.
The TD then subsided, and dopaminergic receptor functioning
recovered. Under this status, aripiprazole would alternatively
further downregulate dopaminergic neurotransmission in an
elderly female with age-related neuronal loss and reduced brain
reserve. Parkinsonian symptoms appeared instead of TD at this
stage. As the functioning of acetylcholine was decreased by
increasing the trihexyphenidyl dosage, the balance between
cholinergic and dopaminergic transmission was reestablished and
Parkinsonian symptoms disappeared. Although this patient had
several risk factors for developing TD and Parkinsonian symptoms
(i.e., female sex, old age, and prior extrapyramidal adverse effects)3,
remission with no abnormal movement was successfully main-
tained for the following 12 months, indicating that the dopamine
partial agonist is relatively safe for long-term use. The clear
temporal association of initiation of aripiprazole, discontinuance of
amantadine, and reduction of the trihexyphenidyl dosage with
subsequent remission of TD suggests the possible etiological effect
of aripiprazole on TD onset in combinationwith amantadine and/or
trihexyphenidyl.
4. Conclusions
In line with previous reports, this report heightens the aware-
ness of clinicians of the potential risk of various movement disor-
ders during aripiprazole therapy for elderly patients. Interventions
for extrapyramidal symptoms must to be tailored to the patient’s
state. However, the applicability of this report is limited as it is
a single-case report.
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